Repeated loco-regional therapies for hepatocellular carcinoma is associated with inferior outcome after living donor liver transplantation in cirrhotic patients

被引:3
|
作者
Tsou, Yi-Fan [1 ]
Lin, Niang-Cheng [1 ]
Hsia, Cheng-Yuan [1 ,2 ]
Loong, Che-Chuan [1 ,2 ]
Tsai, Hsin-Lin [1 ,3 ]
Chen, Cheng-Yen [1 ]
Lei, Hao-Jan [1 ,2 ]
Chou, Shu-Cheng [1 ,2 ]
Chung, Meng-Hsuan [1 ]
Kuo, Fang-Cheng [1 ]
Liu, Chin-Su [1 ,3 ]
机构
[1] Taipei Vet Gen Hosp, Dept Surg, Div Transplantat Surg, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Dept Surg, Div Gen Surg, Taipei, Taiwan
[3] Taipei Vet Gen Hosp, Dept Surg, Div Pediat Surg, Taipei, Taiwan
关键词
Hepatocellular carcinoma; Liver transplantation; Living donor liver transplantation; Loco-regional therapy; Outcomes; CHEMOEMBOLIZATION; IMPACT;
D O I
10.1097/JCMA.0000000000000670
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Liver transplantation is the definitive treatment for defined stage hepatocellular carcinoma (HCC) in cirrhotic patients. Loco-regional therapy (LRT) may be considered before transplantation to prevent the disease progression and the patient from dropping out of the waiting list. This study aims to evaluate the impact of repeated pretransplant LRTs on the long-term outcomes in HCC liver transplant recipients. Methods: Between 2004 and 2019, living donor liver transplantation (LDLT) recipients with viable HCC on the explant livers were enrolled. Uni- and multivariate analysis was performed with the Cox regression model to stratify the risk factors associated with HCC recurrence and patent survival after LDLT. Results: A total of 124 patients were enrolled, in which 65.3% (n = 81) were Barcelona Clinic Liver Cancer classification stage B or D and 89% (n = 110) had advanced fibrosis or cirrhosis on the explanted livers. After a median follow-up of 41 months (IQR: 24-86.5), there were 18 cases (13.7%) of HCC recurrence. Univariate analysis showed that the model of end-stage liver disease and Child-Turcotte-Pugh score, pretransplant alpha-fetoprotein value (>500 ng/ml), repeated pretransplant LRTs (N > 4), increased tumor numbers and maximal size, presence of microvascular invasion, and the histological grading of the tumors are risk factors of inferior outcomes. In multivariate analysis, only repeated pretransplant LRTs (N > 4) had a significant impact on both the overall- and recurrence-free survival. The impact of pretransplant LRT was consistently significant among subgroups based on their LRT episodes (N = 0, 1-4, >4 respectively). Conclusion: Repeated LRT for HCC can be associated with the risk of tumor recurrence and inferior patient survival after LDLT in cirrhotic patients. Early referral of those eligible for transplantation may improve the treatment outcomes in these patients.
引用
收藏
页码:317 / 323
页数:7
相关论文
共 50 条
  • [1] Repeated loco-regional therapies for hepatocellular carcinoma is associated with inferior outcome after living donor liver transplantation in cirrhotic patients: Erratum (vol 85, pg 317, 2022)
    Tsou, Yi-Fan
    Lin, Niang-Cheng
    Hsia, C. Y.
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2023, 86 (10) : 946 - 946
  • [2] Outcomes associated with the intention of loco-regional therapy prior to living donor liver transplantation for hepatocellular carcinoma
    Wu, Tsung-Han
    Wang, Yu-Chao
    Cheng, Chih-Hsien
    Lee, Chen-Fang
    Wu, Ting-Jung
    Chou, Hong-Shiue
    Chan, Kun-Ming
    Lee, Wei-Chen
    WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2020, 12 (01): : 17 - 27
  • [3] Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: Selecting an optimal therapy
    Thomas J Byrne
    Jorge Rakela
    World Journal of Transplantation, 2016, (02) : 306 - 313
  • [4] The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma
    Yao, FY
    Kinkhabwala, M
    LaBerge, JM
    Bass, NM
    Brown, R
    Kerlan, R
    Venook, A
    Ascher, NL
    Emond, JC
    Roberts, JP
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (04) : 795 - 804
  • [5] Loco-regional hepatocellular carcinoma treatment services as a bridge to liver transplantation
    Sophia Schmitz
    Georg Lurje
    Florian Ulmer
    Anne Andert
    Philipp Bruners
    Maximilian Schulze-Hagen
    Ulf Neumann
    Wenzel Schoening
    Hepatobiliary & Pancreatic Diseases International, 2019, 18 (03) : 228 - 236
  • [6] Loco-regional hepatocellular carcinoma treatment services as a bridge to liver transplantation
    Schmitz, Sophia
    Lurje, Georg
    Ulmer, Florian
    Andert, Anne
    Bruners, Philipp
    Schulze-Hagen, Maximilian
    Neumann, Ulf
    Schoening, Wenzel
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2019, 18 (03) : 228 - 236
  • [7] Efficacy of loco-regional treatment for hepatocellular carcinoma prior to living donor liver transplantation: a report from a single center in Egypt
    Shaker, Mohammad Kamal
    Montasser, Iman F.
    Sakr, Mohamed
    Elgharib, Mohamed
    Dabbous, Hany M.
    Ebada, Hend
    El Dorry, Ahmed
    Bahaa, Mohamed
    El Meteini, Mahmoud
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2018, 5 : 29 - 36
  • [8] Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation
    Choi, Ho Joong
    Kim, Dong Goo
    Na, Gun Hyung
    Han, Jae Hyun
    Hong, Tae Ho
    You, Young Kyoung
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (29) : 4737 - 4744
  • [9] Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation
    Ho Joong Choi
    Dong Goo Kim
    Gun Hyung Na
    Jae Hyun Han
    Tae Ho Hong
    Young Kyoung You
    World Journal of Gastroenterology, 2013, (29) : 4737 - 4744
  • [10] Outcome of patients with hepatocellular carcinoma after cadaveric and living donor liver transplantation.
    Karasu, Zeki
    Akyidiz, Murat
    Yilmaz, Funda
    Aydin, Unal
    Akarca, Ulus
    Ersoz, Galip
    Gunsar, Fulya
    Ilter, Tankut
    Zeytunlu, Murat
    Kilic, Murat
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 379 - 379